Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01156571 · ClinicalTrials.gov registry record · Phase 3
A Clinical Trial Comparing Cangrelor to Clopidogrel Standard Therapy in Subjects Who Require Percutaneous Coronary Intervention (PCI) (CHAMPION PHOENIX)
A Phase 3 study, sponsored by The Medicines Company.
- Completed
- Registry status
- Phase 3
- Development phase
- 11,145
- Enrollment target
NCT01156571: Completed Phase 3 study, sponsored by The Medicines Company.
NCT01156571 is a Phase 3 study that has completed, run by The Medicines Company. The registered enrollment target is 11,145 participants, above the 771-participant average among 15,282 other Phase 3 trials with a reported enrollment target (1346% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01156571, a Phase 3 study, has completed, sponsored by The Medicines Company.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 11,145 participants
- Enrollment target
Study Summary
The study is designed to compare the efficacy and safety profile of cangrelor to standard of care in patients require percutaneous coronary intervention (PCI).
Primary Outcome
Clinical Events Committee (CEC)-adjudicated results (modified intent-to-treat \[mITT\] population)
Interventions
- DRUG cangrelor P2Y12 (platelet) inhibitor
- DRUG Clopidogrel - 300 or 600 mg (study arm)
- DRUG Clopidogrel 600 mg post cangrelor
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 11,145 participants |
| Start Date | 2010-09 |
| Est. Completion | 2012-12 |
| Phase | Phase 3 |
What the finished NCT01156571 record still lists
NCT01156571 is an interventional study that assigns participants to a tested intervention. Its 11,145 participants enrollment target places it among the larger protocols in the corpus, above the 771-participant average among 15,282 other Phase 3 trials with a reported enrollment target (1346% higher).
The record links to 0 conditions, and to 3 interventions - of which cangrelor P2Y12 (platelet) inhibitor is the first listed.
NCT01156571 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01156571 about?
NCT01156571 is a clinical study titled "A Clinical Trial Comparing Cangrelor to Clopidogrel Standard Therapy in Subjects Who Require Percutaneous Coronary Intervention (PCI) (CHAMPION PHOENIX)". The study is designed to compare the efficacy and safety profile of cangrelor to standard of care in patients require percutaneous coronary intervention (PCI).
What is the current status of trial NCT01156571?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 11,145 participants. The study started on 2010-09. Estimated completion is 2012-12.
What interventions are being tested in trial NCT01156571?
The interventions under investigation include: cangrelor P2Y12 (platelet) inhibitor (DRUG), Clopidogrel - 300 or 600 mg (study arm) (DRUG), Clopidogrel 600 mg post cangrelor (DRUG).
Who is sponsoring clinical trial NCT01156571?
This trial is sponsored by The Medicines Company, which has 35 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01156571's enrollment target sits among peer trials
11,145 22nd of 2000 higher than 1,979 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06531824 · 11,000 participants · Phase 3
EASi-KIDNEY™ (The Studies of Heart & Kidney Protection With BI 690517 in Combination With Empagliflozin)
- NCT07136012 · 11,000 participants · Phase 3
OCEAN(a)-PreEvent - Olpasiran Trials of Cardiovascular Events And LipoproteiN(a) Reduction to Prevent First Major Cardiovascular Events
- NCT07181109 · 11,000 participants · Phase 3
Zilebesiran in Patients With Hypertension Not Adequately Controlled and With Either Established Cardiovascular Disease or High Risk for Cardiovascular Disease
- NCT06677060 · 11,300 participants · Phase 3
Phase III Study Investigating Heart Failure and Cardiovascular Death With Baxdrostat in Combination With Dapagliflozin
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia